Feature

VIDEO: Keep index of suspicion high for groups at risk of suicide and substance abuse


 

AT AN EXPERT PANEL ON SUICIDE AND OPIOID DEATHS

WASHINGTONSuicides and opioid-related drug deaths are on parallel increases, devastating the same groups and the same communities, according to Alex Crosby, MD, senior adviser at the Centers for Disease Control and Prevention’s division of violence prevention at the National Center for Injury Prevention and Control.

Suicides increased by 25% during 2000-2015, and drug deaths – most notably, opioid-related deaths – have quadrupled since 1999. These increases strike the same groups: men, working-age adults, whites, Native Americans and Alaskan natives, and rural communities.

So consistent are the overlaps that primary care providers should view these demographics as red flags when such patients present with depression or pain complaints, Dr. Crosby said in an interview at an event sponsored by the Education Development Center and the National Alliance for Suicide Prevention. Vigilance in primary care settings is especially important, because many patients don’t have access to behavioral health specialists.

“As clinicians, we need to have a high index of suspicion, know what questions to ask, and to go a little bit deeper, beyond the presenting complaint,” he said. “Often, people with psychiatric illnesses [that predispose them to suicide and substance abuse] are going to their primary care provider first, because they don’t have access to behavioral health services. The family medicine practitioner, the internist, even the pediatrician, have to be aware of this. And clinicians need to have index of suspicion, and ask questions that go a little deeper than the presenting complaint was.”

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Alcohol misuse universal screening effective and efficient
MDedge Family Medicine
Three percent of high school seniors report using synthetic cannabinoids
MDedge Family Medicine
FDA advisory committee rejects opioids in children’s cough syrup
MDedge Family Medicine
Psychological analysis skills can lead to safer pain care
MDedge Family Medicine
FDA gives nod to first mobile app for substance use disorders
MDedge Family Medicine
E-cigarettes most popular among youngest adults
MDedge Family Medicine
Do not withhold opioid addiction drugs from patients taking benzodiazepines
MDedge Family Medicine
One in four ‘control’ mothers in NAS study tests positive for drug use
MDedge Family Medicine
Sharing drug paraphernalia alone didn’t transmit HCV
MDedge Family Medicine
Opioid deaths and suicides – twin tragedies that need a community-wide response
MDedge Family Medicine

Related Articles